drugset / Trial / NCT05569538
Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis
Phase 2
Unknown
40 enrolled
The University of Hong Kong
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, Phase 2 study of bomedemstat (IMG-7289), an inhibitor of lysine-specific demethylase 1 (LSD1), in combination with JAK inhibition (JAKi) in patients with myelofibrosis.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bomedemstat | Small molecule | 0.4 mg/kg | Oral |